Selected Quarterly Financial Data (Unaudited) (Details) (USD $) Share data in Thousands, except Per Share data, unless otherwise specified	3 Months Ended											12 Months Ended			0 Months Ended	3 Months Ended		12 Months Ended
	Dec. 28, 2013		Sep. 28, 2013	Jun. 29, 2013		Mar. 30, 2013	Dec. 29, 2012	Sep. 29, 2012	Jun. 30, 2012		Mar. 31, 2012	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011	Oct. 16, 2012 MicroProbe	Dec. 29, 2012 MicroProbe	Jun. 30, 2012 MicroProbe	Dec. 28, 2013 MicroProbe	Dec. 29, 2012 MicroProbe
Quarterly Financial Data [Abstract]
Revenue, Net	$ 48,546,000	[1]	$ 67,634,000	$ 62,733,000	[2]	$ 52,620,000	$ 47,654,000	$ 41,262,000	$ 54,813,000	[3]	$ 34,806,000	$ 231,533,000	$ 178,535,000	$ 169,325,000
Cost of revenues	44,288,000	[1]	55,088,000	46,328,000	[2]	43,545,000	50,798,000	33,110,000	38,646,000	[3]	30,650,000	189,249,000	153,204,000	148,367,000
Gross profit	4,258,000		12,546,000	16,405,000		9,075,000	(3,144,000)	8,152,000	16,167,000		4,156,000	42,284,000	25,331,000	20,958,000
Research and Development Expense	9,994,000	[1]	10,301,000	10,915,000	[2]	10,929,000	9,775,000	8,573,000	10,935,000	[3]	10,847,000	42,139,000	40,130,000	43,544,000
Selling, General and Administrative Expense	12,160,000	[1]	12,952,000	13,487,000	[2]	14,618,000	14,958,000	11,594,000	11,531,000	[3]	11,148,000	53,217,000	49,231,000	46,705,000
Loss on sale of subsidiary	0		0	300,000		0	0	0	0		0	300,000	0	0
Restructuring Charges	443,000	[1]	143,000	92,000	[2]	3,980,000	333,000	2,481,000	136,000	[3]	(33,000)	4,658,000	2,917,000	522,000
Impairment of long-lived assets	567,000	[1]	15,000	121,000	[2]	58,000	49,000	143,000	61,000	[3]	168,000	761,000	421,000	549,000
Gain on settlement of litigation	0		0	0		0	(3,250,000)	0	0		0	0	(3,250,000)	0	3,300,000
Total operating expenses	23,164,000		23,411,000	24,915,000		29,585,000	21,865,000	22,791,000	22,663,000		22,130,000	101,075,000	89,449,000	91,320,000
Operating loss	(18,906,000)		(10,865,000)	(8,510,000)		(20,510,000)	(25,009,000)	(14,639,000)	(6,496,000)		(17,974,000)	(58,791,000)	(64,118,000)	(70,362,000)		6,400,000
Interest income, net	88,000	[1]	95,000	96,000	[2]	107,000	134,000	163,000	182,000	[3]	212,000	386,000	691,000	1,404,000
Other income, net	82,000	[1]	(91,000)	209,000	[2]	423,000	334,000	171,000	546,000	[3]	410,000	623,000	1,461,000	1,076,000
Loss before Income taxes	(18,736,000)		(10,861,000)	(8,205,000)		(19,980,000)	(24,541,000)	(14,305,000)	(5,768,000)		(17,352,000)	(57,782,000)	(61,966,000)	(67,882,000)
Benefit from income taxes	53,000	[1]	(147,000)	202,000	[2]	(207,000)	(25,144,000)	173,000	(1,551,000)	[3]	102,000	(99,000)	(26,420,000)	(1,901,000)	3,300,000	25,500,000	1,600,000
Net loss	(18,789,000)		(10,714,000)	(8,407,000)		(19,773,000)	603,000	(14,478,000)	(4,217,000)		(17,454,000)	(57,683,000)	(35,546,000)	(65,981,000)
Earnings Per Share, Basic	$ (0.34)		$ (0.20)	$ (0.16)		$ (0.37)	$ 0.01	$ (0.29)	$ (0.08)		$ (0.35)
Earnings Per Share, Diluted	$ (0.34)		$ (0.20)	$ (0.16)		$ (0.37)	$ 0.01	$ (0.29)	$ (0.08)		$ (0.35)
Weighted Average Number of Shares Outstanding, Basic	54,608		54,437	54,105		53,664	52,745	50,154	49,817		49,487	54,204	50,551	50,521
Basic and diluted (shares)	54,608	[1]	54,437	54,105	[2]	53,664	52,921	50,154	49,817	[3]	49,487	54,204	50,551	50,521
BusinessCombinationRevenueOfAcquireeSinceAcquisitionDateActual																19,800,000		93,200,000	19,800,000
Amortization of Intangible Assets												16,694,000	6,566,000	1,179,000		5,400,000
Release Of Pre Existing Backlog																2,600,000
Inventory fair value step-up																3,500,000
Step Up Depreciation Charge																$ 200,000

[1] In the fourth quarter of fiscal 2012, we recorded an income tax benefit in the amount of $25.5 million from the release of deferred tax asset valuation allowances due to deferred tax liabilities established on the acquired identifiable intangible assets from our acquisition of MicroProbe and $3.3 million benefit from the settlement of patent litigation in conjunction with the acquisition of MicroProbe on October 16, 2012. The fourth quarter of fiscal 2012 includes the following Microprobe operating activity: $19.8 million in revenue, $5.4 million amortization of intangibles, $2.6 million release of pre-existing backlog, $3.5 million release of inventory fair value step-up and $0.2 million charge for step-up depreciation on fixed assets resulting in a net loss of $6.4 million.(3)In the second quarter of fiscal 2012, we recorded a tax benefit in the amount of $1.6 million from the release of a deferred tax valuation allowance recorded in a non-U.S. jurisdiction. This benefit resulted in an overall income tax benefit, rather than an income tax provision in the second quarter of fiscal 2012.

[2] In the fourth quarter of fiscal 2012, we recorded an income tax benefit in the amount of $25.5 million from the release of deferred tax asset valuation allowances due to deferred tax liabilities established on the acquired identifiable intangible assets from our acquisition of MicroProbe and $3.3 million benefit from the settlement of patent litigation in conjunction with the acquisition of MicroProbe on October 16, 2012. The fourth quarter of fiscal 2012 includes the following Microprobe operating activity: $19.8 million in revenue, $5.4 million amortization of intangibles, $2.6 million release of pre-existing backlog, $3.5 million release of inventory fair value step-up and $0.2 million charge for step-up depreciation on fixed assets resulting in a net loss of $6.4 million.

[3] In the second quarter of fiscal 2013, we recorded a $0.3 million loss on the sale of our subsidiary, TMMC. See Note 8 to the Notes to Consolidated Financial Statements for further details relating to the terms of the sale.